GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Inotiv Inc (NAS:NOTV) » Definitions » Shiller PE Ratio

Inotiv (Inotiv) Shiller PE Ratio : (As of May. 14, 2024)


View and export this data going back to 1997. Start your Free Trial

What is Inotiv Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Inotiv Shiller PE Ratio Historical Data

The historical data trend for Inotiv's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inotiv Shiller PE Ratio Chart

Inotiv Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Inotiv Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Inotiv's Shiller PE Ratio

For the Diagnostics & Research subindustry, Inotiv's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inotiv's Shiller PE Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Inotiv's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Inotiv's Shiller PE Ratio falls into.



Inotiv Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Inotiv's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Inotiv's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.6/129.4194*129.4194
=-0.600

Current CPI (Dec. 2023) = 129.4194.

Inotiv Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -0.030 99.695 -0.039
201406 0.020 100.560 0.026
201409 -0.050 100.428 -0.064
201412 0.010 99.070 0.013
201503 -0.010 99.621 -0.013
201506 0.160 100.684 0.206
201509 -0.090 100.392 -0.116
201512 -0.060 99.792 -0.078
201603 -0.030 100.470 -0.039
201606 -0.050 101.688 -0.064
201609 -0.250 101.861 -0.318
201612 0.002 101.863 0.003
201703 0.050 102.862 0.063
201706 0.030 103.349 0.038
201709 0.030 104.136 0.037
201712 0.003 104.011 0.004
201803 0.010 105.290 0.012
201806 -0.010 106.317 -0.012
201809 -0.020 106.507 -0.024
201812 -0.010 105.998 -0.012
201903 -0.060 107.251 -0.072
201906 -0.040 108.070 -0.048
201909 0.030 108.329 0.036
201912 -0.130 108.420 -0.155
202003 -0.050 108.902 -0.059
202006 -0.080 108.767 -0.095
202009 -0.160 109.815 -0.189
202012 -0.030 109.897 -0.035
202103 -0.060 111.754 -0.069
202106 0.170 114.631 0.192
202109 0.060 115.734 0.067
202112 -3.930 117.630 -4.324
202203 -0.240 121.301 -0.256
202206 -0.150 125.017 -0.155
202209 -9.540 125.227 -9.859
202212 -3.410 125.222 -3.524
202303 -0.390 127.348 -0.396
202306 0.070 128.729 0.070
202309 -0.380 129.860 -0.379
202312 -0.600 129.419 -0.600

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Inotiv  (NAS:NOTV) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Inotiv Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Inotiv's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Inotiv (Inotiv) Business Description

Traded in Other Exchanges
Address
2701 Kent Avenue, West Lafayette, IN, USA, 47906
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery and development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, it supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through the RMS segment, it offers access to a wide range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas. It earns maximum revenue from RMS Segment.
Executives
John Gregory Beattie officer: Chief Operating Officer C/O BIOANALYTICAL SYSTEMS, INC., 2701 KENT AVENUE, WEST LAFAYETTE IN 47906
Michael Garrett officer: Chief Commercial Officer 250 PEHLE DRIVE, SUITE 601, SADDLE BROOK NJ 07663
Andrea Castetter officer: SVP, Gen. Counsel & Secretary 2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
Mary Theresa Coelho director 52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017
John E Sagartz director, officer: Chief Strategy Officer 19 WORTHINGTON ACCESS DRIVE, MARYLAND HEIGHTS MO 63043
David Landman director 2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
Robert Jr. Leasure director, officer: President and CEO C/O BIOANALYTICAL SYSTEMS, INC., 2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
Beth Taylor officer: Chief Financial Officer 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Jeffrey Arthur Krupp officer: Chief Human Resources Officer 2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
William D Pitchford officer: Chief Human Resources Officer 1000 SAGAMORE PARKWAY SOUTH, LAFAYETTE IN 47905
R Matthew Neff director 535 N. COLLEGE DRIVE, CARMEL IN 46032
Jeffrey Brennan Freeman officer: VP-Finance & Corp. Controller 2701 KENT AVENUE, WEST LAFAYETTE IN 47906-1382
Davis Gregory Cole director C/O BIOANALYTICAL SYSTEMS, INC., 2701 KENT AVENUE, WEST LAFAYETTE IN 47906
Nigel Brown director 250 PEHLE AVENUE, SUITE 600, SADDLE BROOK NJ 07663
Scott Cragg director 660 MADISON AVENUE, NEW YORK NY 10065